Gamma-linolenic acid modulates the response of multidrug-resistant K562 leukemic cells to anticancer drugs

Toxicology in Vitro

Volumn 23, Issue 4, 2009, Pages 634-639

  Kong, Xiuqin ^a   Ge, Haitao ^b   Chen, Li ^a   Liu, Zhili ^c   Yin, Zhimin ^a   Li, Ping ^b   Li, Mei ^c  

^a NANJING NORMAL UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c NANJING UNIVERSITY   (China)

Author keywords

Drug resistance; Gamma linolenic acid; Leukemia; P glycoprotein

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GAMMA LINOLENIC ACID; GLYCOPROTEIN P; MITOMYCIN; RHODAMINE 123; VINCRISTINE;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL VIABILITY; CONCENTRATION RESPONSE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG RESPONSE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INHIBITION KINETICS; LEUKEMIA CELL; MULTIDRUG RESISTANCE; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GAMMA-LINOLENIC ACID; HUMANS; K562 CELLS; P-GLYCOPROTEIN;

EID: 67349183356     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tiv.2009.02.010     Document Type: Article

References (36)

1. Babcock T.A., Kurland A., Helton W.S., Rahman A., Anwar K.N., and Espat N.J. Inhibition of activator protein-1 transcription factor activation by omega-3 fatty acid modulation of mitogen-activated protein kinase signaling kinases. J. Parenter. Enteral. Nutr. 27 (2003) 176-180
2. Balayssac D., Authier N., Cayre A., and Coudore F. Does inhibition of P-glycoprotein lead to drug-drug interactions?. Toxicol. Lett. 156 (2005) 319-329
3. Barancik M., Bohacova V., Kvackajova J., Hudecova S., Krizanova O., and Breier A. SB203580, a specific inhibitor of p38-MAPK pathway, is a new reversal agent of P-glycoprotein-mediated multidrug resistance. Eur. J. Pharm. Sci. 14 (2001) 29-36
4. Bentires-Alj M., Barbu V., Fillet M., Chariot A., Relic B., Jacobs N., Gielen J., Merville M.P., and Bours V. NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 22 (2003) 90-97
5. Che X.F., Nakajima Y., Sumizawa T., Ikeda R., Ren X.Q., Zheng C.L., Mukai M., Furukawa T., Haraguchi M., Gao H., Sugimoto Y., and Akiyama S. Reversal of P-glycoprotein mediated multidrug resistance by a newly synthesized 1,4-benzothiazipine derivative, JTV-519. Cancer Lett. 187 (2002) 111-119
6. Chen Y., and Hughes-Fulford M. Prostaglandin E2 and the protein kinase A pathway mediate arachidonic acid induction of c-fos in human prostate cancer cells. Br. J. Cancer 82 (2000) 2000-2006
7. Chou T.C., and Talalay P. Generalized equations for the analysis of inhibitors of Michaelis-Menten and higher order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur. J. Biochem. 115 (1981) 207-216
8. Chu E.S., Yow C.M., Shi M., and Ho R.J. Effects of photoactivated 5-aminolevulinic acid hexyl ester on MDR1 over-expressing human uterine sarcoma cells. Toxicol. Lett. 181 (2008) 7-12
9. Chung S., Park S., and Yang C.H. Unsaturated fatty acids bind Myc-Max transcription factor and inhibit Myc-Max-DNA complex formation. Cancer Lett. 188 (2002) 153-162
10. Davies C.L., Loizidou M., Cooper A.J., and Taylor I. Effect of gamma-linolenic acid on cellular uptake of structurally related anthracyclines in human drug sensitive and multidrug resistant bladder and breast cancer cell lines. Eur. J. Cancer 35 (1999) 1534-1540
11. Fujita T., Washio K., Takabatake D., Takahashi H., Yoshitomi S., Tsukuda K., Ishibe Y., Ogasawara Y., Doihara H., and Shimizu N. Proteasome inhibitors can alter the signaling pathways and attenuate the P-glycoprotein-mediated multidrug resistance. Int. J. Cancer 117 (2005) 670-682
12. Gao P., Zhou G.Y., Guo L.L., Zhang Q.H., Zhen J.H., Fang A.J., and Lin X.Y. Reversal of drug resistance in breast carcinoma cells by anti-mdr1 ribozyme regulated by the tumor-specific MUC-1 promoter. Cancer Lett. 256 (2007) 81-89
13. Harris N.M., Anderson W.R., Lwaleed B.A., Cooper A.J., Birch B.R., and Solomon L.Z. Epirubicin and meglumine gamma-linolenic acid: a logical choice of combination therapy for patients with superficial bladder carcinoma. Cancer 97 (2003) 71-78
14. Hennessy M., and Spiers J.P. A primer on the mechanics of P-glycoprotein the multidrug transporter. Pharmacol. Res. 55 (2007) 1-15
15. Holland M.L., Panetta J.A., Hoskins J.M., Bebawy M., Roufogalis B.D., Allen J.D., and Arnold J.C. The effects of cannabinoids on P-glycoprotein transport and expression in multidrug resistant cells. Biochem. Pharmacol. 71 (2006) 1146-1154
16. Ji B.S., He L., and Liu G.Q. Reversal of p-glycoprotein-mediated multidrug resistance by CJX1, an amlodipine derivative, in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. Life Sci. 77 (2005) 2221-2232
17. Jump D.B. Fatty acid regulation of gene transcription. Crit. Rev. Clin. Lab. Sci. 41 (2004) 41-78
18. Kenny F.S., Pinder S.E., Ellis I.O., Gee J.M., Nicholson R.I., Bryce R.P., and Robertson J.F. Gamma linolenic acid with tamoxifen as primary therapy in breast cancer. Int. J. Cancer. 85 (2000) 643-648
19. Kong X., Ge H., Hou L., Shi L., and Liu Z. Induction of apoptosis in K562/ADM cells by gamma-linolenic acid involves lipid peroxidation and activation of caspase-3. Chem. Biol. Interact. 162 (2006) 140-148
20. Lee M., and Bae M.A. Docosahexaenoic acid induces apoptosis in CYP2E1-containing HepG2 cells by activating the c-Jun N-terminal protein kinase related mitochondrial damage. J. Nutr. Biochem. 18 (2007) 348-354
21. Leslie E.M., Deeley R.G., and Cole S.P. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol. 204 (2005) 216-237
22. Liu Q.Y., and Tan B.K. Effects of cis-unsaturated fatty acids on doxorubicin sensitivity in P388/DOX resistant and P388 parental cell lines. Life Sci. 67 (2000) 1207-1218
23. Majumder S., Dutta P., Mukherjee P., Datta E.R., Efferth T., Bhattacharya S., and Choudhuri S.K. Reversal of drug resistance in P-glycoprotein-expressing T-cell acute lymphoblastic CEM leukemia cells by copper N-(2-hydroxy acetophenone) glycinate and oxalyl bis (N-phenyl) hydroxamic acid. Cancer Lett. 244 (2006) 16-23
24. Menendez J.A., del M.B., Montero S., Sevilla E., Escrich E., Solanas M., Cortes-Funes H., and Colomer R. Effects of gamma-linolenic acid and oleic acid on paclitaxel cytotoxicity in human breast cancer cells. Eur. J. Cancer 37 (2001) 402-413
25. Menendez J.A., Ropero S., del B.M., Montero S., Solanas M., Escrich E., Cortes-Funes H., and Colomer R. Synergistic interaction between vinorelbine and gamma-linolenic acid in breast cancer cells. Breast Cancer Res. Treat. 72 (2002) 203-219
26. Menendez J.A., Colomer R., and Lupu R. Omega-6 polyunsaturated fatty acid gamma-linolenic acid (18:3n-6) is a selective estrogen-response modulator in human breast cancer cells: gamma-linolenic acid antagonizes estrogen receptor-dependent transcriptional activity, transcriptionally represses estrogen receptor expression and synergistically enhances tamoxifen and ICI 182, 780 (Faslodex) efficacy in human breast cancer cells. Int. J. Cancer. 109 (2004) 949-954
27. Menendez J.A., Ropero S., Lupu R., and Colomer R. Omega-6 polyunsaturated fatty acid gamma-linolenic acid (18:3n-6) enhances docetaxel (Taxotere) cytotoxicity in human breast carcinoma cells: Relationship to lipid peroxidation and HER-2/neu expression. Oncol. Rep. 11 (2004) 1241-1252
28. Meschini S., Marra M., Calcabrini A., Monti E., Gariboldi M., Dolfini E., and Arancia G. Role of the lung resistance-related protein (LRP) in the drug sensitivity of cultured tumor cells. Toxicol. In Vitro 16 (2002) 389-398
29. Miao Z.H., and Ding J. Transcription factor c-Jun activation represses mdr-1 gene expression. Cancer Res. 63 (2003) 4527-4532
30. Ponce L.V., and Barrera-Rodriguez R. Changes in P-glycoprotein activity are mediated by the growth of a tumour cell line as multicellular spheroids. Cancer Cell Int. 5 (2005) 20
31. Ross J.A., Maingay J.P., Fearon K.C., Sangster K., and Powell J.J. Eicosapentaenoic acid perturbs signalling via the NFkappaB transcriptional pathway in pancreatic tumour cells. Int. J. Oncol. 23 (2003) 1733-1738
32. Shen S.H., Gu L.J., Liu P.Q., Ye X., Chang W.S., and Li B.S. Comparative proteomic analysis of differentially expressed proteins between K562 and K562/ADM cells. Chin. Med. J. 121 (2008) 463-468
33. Topaly J., Zeller W.J., and Fruehauf S. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia 15 (2001) 342-347
34. Van T.O. The importance of drug-transporting P-glycoproteins in toxicology. Toxicol. Lett. 120 (2001) 31-41
35. Varma M.V., Ashokraj Y., Dey C.S., and Panchagnula R. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol. Res. 48 (2003) 347-359
36. Xue H., Wan M., Song D., Li Y., and Li J. Eicosapentaenoic acid and docosahexaenoic acid modulate mitogen-activated protein kinase activity in endothelium. Vasc. Pharmacol. 44 (2006) 434-439